HONG KONG, Oct. 22, 2012 /PRNewswire-FirstCall/ -- China Cord Blood Corporation (NYSE:CO) ("CCBC" or the "Company"), the first and largest cord blood banking operator in China, today announced that the Company repurchased an aggregate of 6,041,980 ordinary shares for a total consideration of approximately $16.4 million since April 1, 2012. The total number of shares issued and outstanding as of the date hereof is 73,140,147, with 6,041,980 shares being held as treasury shares. On July 31, 2012, the Company adopted a new $20 million share repurchase mandate, as the prior $15 million share repurchase mandate expired. Under the existing mandate, which will expire on July 31, 2013, the Company has approximately $12.6 million available for repurchase.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest cord blood banking operator in
China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit our website at
Safe Harbor Statement
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts